Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20883048 | 0.86 | LCK (0.45) | LCKCA1CA2PI4KBATR | |
| SCHEMBL13801888 | 0.81 | DYRK1A (0.44) | — | |
| SCHEMBL16753973 | 0.81 | LCK (0.53) | LCKCA1CA2PI4KBATR | |
| SCHEMBL25403792 | 0.81 | LCK (0.53) | LCKCA1CA2PI4KBATR | |
| SCHEMBL25261549 | 0.81 | LCK (0.53) | LCKCA1CA2PI4KBATR | |
| Hydrochloric Acid SCHEMBL25403795 | 0.79 | LCK (0.52) | LCKCA1CA2PI4KBATR | |
| SCHEMBL1268366 | 0.79 | LCK (0.46) | LCKCA1CA2PI4KBATR | |
| SCHEMBL25295310 | 0.77 | LCK (0.53) | LCKCA1CA2PI4KB | |
| SCHEMBL1563222 | 0.76 | LCK (0.48) | LCKCA1CA2PI4KB | |
| SCHEMBL28816640 | 0.75 | LCK (0.47) | LCKCA1CA2PI4KBATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111148743-B | Inhibition of ubiquitin-specific peptidase 30 | 福马治疗有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3692028-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | Forma Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| CN-111148743-A | Inhibition of ubiquitin-specific peptidase 30 | 福马治疗有限公司 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019071073-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | LCK 3555/4885CA1 2800/4885CA2 3861/4885 |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | USP30, UCHL1, UCHL3 | LCK 3965/4885CA1 2102/4885CA2 3640/4885 |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | LCK 3555/4885CA1 2800/4885CA2 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.